Provided by Tiger Trade Technology Pte. Ltd.

Adaptive Biotechnologies Corp

28.35
+0.98003.58%
Post-market: 28.350.9800+3.58%16:00 EDT
Volume:1.55M
Turnover:43.65M
Market Cap:4.53B
PE:-68.93
High:28.41
Open:27.59
Low:27.31
Close:27.37
52wk High:29.96
52wk Low:12.00
Shares:159.76M
Float Shares:125.00M
Volume Ratio:0.54
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4113
EPS(LYR):-0.3922
ROE:-38.76%
ROA:-4.12%
PB:31.69
PE(LYR):-72.29

Loading ...

Adaptive Biotechnologies is Maintained at Buy by Guggenheim

Dow Jones
·
Oct 01

Will NCCN Names MRD Test Change Adaptive Biotechnologies Stock Narrative

Simply Wall St.
·
Oct 01

Adaptive Biotechnologies Highlights MRD Testing Role in New Myeloma Cure Definition from International Myeloma Society

Reuters
·
Sep 25

Adaptive Biotechnologies Price Target Raised to $34.00/Share from $25.00 by BTIG

Dow Jones
·
Sep 22

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 1,195 Shares for $32,265

Reuters
·
Sep 18

Adaptive Biotechnologies reports update to NCCN guidelines for Multiple Myeloma

TIPRANKS
·
Sep 17

Adaptive Biotechnologies Announces Update to Nccn Guidelines® for Multiple Myeloma, Strengthening Mrd Testing Recommendations and Specifically Referencing Clonoseq®

THOMSON REUTERS
·
Sep 17

Alert Incorrectly Tagged to Adaptive Biotechnologies Withdrawn

Reuters
·
Sep 17

Adaptive Raises $30 Million Series B Led by Tidemark to Bring Agentic Accounting to Construction

THOMSON REUTERS
·
Sep 17

Adaptive Biotechnologies Director Katey Einterz Owen Sells 9,615 Shares for $249,990

Reuters
·
Aug 29

Adaptive Biotechnologies (ADPT), Why Is It Getting Fresh Attention Now?

Simply Wall St.
·
Aug 28

Adaptive Biotechnologies Director Peter M. Neupert Disposes of 124,690 Common Shares for $3.14 Million

Reuters
·
Aug 20

Adaptive Biotechnologies (ADPT) Stock Looks Fair On Cash Flow Yet Rich On Sales

Simply Wall St.
·
Aug 13

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 3,000 Shares for $75,000

Reuters
·
Aug 13

Adaptive Biotechnologies is Maintained at Overweight by Piper Sandler

Dow Jones
·
Aug 04

U.S. Research Roundup-Cloudflare, Replimune, Walmart

Reuters
·
Aug 04

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 1,299 Common Shares for $31,176

Reuters
·
Aug 04

Veracyte Q2 Revenue Rises on Decipher and Afirma Test Sales

Reuters
·
Jul 31

Fulgent Genetics Q2 Revenue Rises 20% Sequentially, Sees Billing System Transition Delay

Reuters
·
Jul 31

CareDx Q2 Revenue Beats Estimates; Outlook Lifted

Reuters
·
Jul 31